Global Primary Hyperoxaluria Treatment Market - 2024-2031

Overview

The global primary hyperoxaluria treatment market reached US$ 168.96 million in 2023 and is expected to reach US$ 365.49 million by 2031, growing at a CAGR of 9.8% during the forecast period 2024-2031.

primary hyperoxaluria is a condition in which a substance known as oxalate accumulates in the renal system and results in the formation of urolithiasis (urinary tract stones), and nephrolithiasis (kidney stones). This occurs as a result of a deficiency or genetic mutations of enzymes involved in the oxalate metabolism. Accumulation of oxalates frequently can lead to chronic kidney disease and ultimately lead to kidney failure.

Primary hyperoxaluria is a very rare condition and it is estimatedly affects 1 to 3 people in 1,000,000 population. The most common treatment options for primary hyperoxaluria are pyridoxine and prescription medicines like Lumasiran and Nedosiran which are approved by the FDA. For patients who are at a higher risk of developing chronic kidney disease, dialysis, and kidney transplantation are the primary treatment options.

Market Dynamics

Drivers

Rising research and development activities

Primary hyperoxaluria is the most severe form of hyperoxaluria and a majority of patients are diagnosed with the primary type. Due to the rarity of the condition, the therapeutic options are limited for these patients. Currently, only 2 drugs were approved by the FDA that primarily aim for this condition. Several companies have been investing in novel products for primary hyperoxaluria treatment. The chances are higher that the novel drug can be designated as an orphan drug and gain a huge marketing potential in the forecast period.

For instance, in October 2023, the U.S. Food and Drug Administration (FDA) approved Rivfloza (nedosiran) injection the legacy of Novo Nordisk for the treatment of children above 9 years of age and adults with primary hyperoxaluria type 1 (PH1). Nedosiran is a once-monthly subcutaneous ribonucleic acid interference (RNAi) therapy that is known to lower urinary oxalate levels.

OxThera. Has recently finished the phase 3 clinical trials for Oxabact. The study evaluated the effect of Oxabact OC5 in PH patients with maintained renal function but with an eGFR below the normal range and an elevated Pox concentration. This 12-month phase III, double-blind, placebo-controlled study barely missed the endpoint.

In addition, several companies have investigational drugs in clinical development for the treatment of PH, including BridgeBio, Chinook Therapeutics, Inc., and BioMarin Pharmaceutical, Inc. If these products get approved, they may revolutionize the treatment of primary hyperoxaluria.

Restraints

The lack of specific treatment options for primary hyperoxaluria is limiting the market growth. The majority of the patients with this condition rely on supportive therapies. Although a couple of therapies were recently approved, they are expensive and may limit their usage in low and middle-income countries, where a majority of the global population lives.

For more details on this report - Request for Sample

Segment Analysis

The global primary hyperoxaluria treatment market is segmented based on type, treatment type, and region.

The medication in the treatment type segment accounted for approximately 67.5% of the global primary hyperoxaluria treatment market share.

The primary goal of primary hyperoxaluria treatment is to reduce the accumulation of oxalic acid in the kidneys and the urinary tract. This can be managed by certain medications such as pyridoxine, potassium citrate, thiazides, magnesium, or orthophosphates. These medications in combination with water intake can further reduce the risk of calcium and oxalate crystallization but often do not entirely prevent stone formation or kidney failure. According to the National Kidney Foundation, about 30% of people living with PH1 may be able to lower their blood oxalate levels with the help of pyridoxine which is available at all pharmacies with a prescription.

Moreover, the FDA has approved 2 novel treatments for primary hyperoxaluria, which have gained huge traction recently. Several other companies have been investing and focusing on the development of novel medications for the same, which are expected to revolutionize primary hyperoxaluria therapeutics.

The dialysis and kidney transplant remain as a final stay of treatment when the patient's prognosis is very severe and leads to kidney damage. Moreover, both dialysis and kidney transplantation are costly procedures, which can create a huge economic burden on the patient. Hence managing the condition through medication remains the primary approach and is recommended my physicians.

Geographical Analysis

Europe is expected to dominate the market with a 39.6% share in the global primary hyperoxaluria treatment market.

The prevalence of primary hyperoxaluria is high in Europe as compared to other regions. As per NORD (National Organization for Rare Disorders) the prevalence of PH type I is at 1-3 cases per 1,000,000 people in the general population with fewer than 1,000 individuals with PH in the United States and the incidence at 1 case per 120,000 live births per year in Europe. Even in North America, PH is thought to be approximately 2.5 times more common in European Americans than African Americans. Considering the current population of Europe i.e., 742 million in 2023, the estimated number of cases in Europe would be between 1400 to 2200 cases, which is higher than number of cases in U.S.

Moreover, the currently approved medications for primary hyperoxaluria are majorly marketed in the Europe. For instance, Alnylam Pharmaceuticals has first launched OXLUMO (Lumasiran) the first approved medication for PH in the U.S., but the company generates majority of the revenue from European countries. In 2023, the company has generated a total sales of US$ 109.8 million of which US$ 60 million are generated from Europe. This is a huge shift from 2022, during which the company generated 37 million in Europe recording a sales increase of 58%.

Market Segmentation

By Type

• Primary Hyperoxaluria Type I
• Primary Hyperoxaluria Type II
• Primary Hyperoxaluria Type III

By Treatment Type

• Medication
  • Pyridoxine
  • Lumasiran
  • Nedosiran
  • Citrates and Bicarbonate Salts
  • Others
• Dialysis
• Transplantation

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major players in the primary hyperoxaluria treatment market include Alnylam Pharmaceuticals, Novo Nordisk A/S., Zhejiang Tianxin Pharmaceutical Co., Ltd., DSM, BASF, Fagron, Pfizer Inc., AdvaCare Pharma, Sanofi and Viatris Inc. among others.

Why Purchase the Report?

• To visualize the global primary hyperoxaluria treatment market segmentation based on type, treatment type, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of primary hyperoxaluria treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global primary hyperoxaluria treatment market report would provide approximately 54 tables, 44 figures, and 187 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies